Autolus Therapeutics PLC (NAS:AUTL)
$ 3.85 0.01 (0.26%) Market Cap: 1.02 Bil Enterprise Value: 314.39 Mil PE Ratio: 0 PB Ratio: 1.76 GF Score: 55/100

Autolus Therapeutics plc - Special Call Transcript

Dec 07, 2020 / 09:00PM GMT
Release Date Price: $11.95 (+13.81%)
Operator

Hello, ladies and gentlemen, and welcome to the Autolus Therapeutics ASH AUTO1 and AUTO3 Data Update. As a reminder, this conference call is being recorded.

I would now like to turn the conference over to your host, Dr. Lucinda Crabtree, Vice President, Investor Relations. Please go ahead.

Lucinda Crabtree
Autolus Therapeutics plc - VP of IR & Corporate Communications

Thank you. Good morning or good afternoon, everyone, and thank you for taking part in today's call on the ASH AUTO1 and AUTO3 Data Update. I am Lucinda Crabtree, Vice President of Investor Relations.

With me today are Dr. Christian Itin, our Chairman and Chief Executive Officer; Dr. Robert Chen, our AUTO3 and lymphoma program lead; Dr. Nushmia Khokhar, our Head of Clinical Development; Brent Rice, our Chief Commercial Officer; Dr. Martin Pulé, our Chief Scientific Officer; and Andrew Oakley, our Chief Financial Officer.

Before we begin, I would like to remind you that during today's call, our discussion will contain forward-looking statements. All statements,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot